| Entries |
| Document | Title | Date |
|---|
| 20080200431 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa - The invention relates to compounds of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R | 08-21-2008 |
| 20080214495 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa - The invention relates to compounds of formula (I), wherein R | 09-04-2008 |
| 20080227752 | Methods to Inhibit Histone Acetyltransferase Using Glycosaminoglycans - The present invention is directed to methods for inhibition of histone acetyltransferases using glycosaminoglycans. The invention is further directed to methods for treating disorders associated with hyperacetylation by administration of glycosaminoglycans to a patient in need thereof. In one preferred embodiment, the glycosaminoglycan is a heparin or heparan sulfate oligosaccharide. Studies show that removal of sulfate residues from the O-positions of either the uronic acid or the glucosamine did not eliminate the inhibitory activity of heparan sulfate. Since a majority of heparan sulfate binding proteins appear to require O-sulfation, molecules without certain O-sulfations can be used to inhibit HATs while not interacting with most known heparin-binding proteins. In addition, specific sequences of heparin/heparan sulfate can be used to specifically inhibit various HATs. | 09-18-2008 |
| 20080269164 | Preparation and Application of Heparin Silver - The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topic topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation. | 10-30-2008 |
| 20080269165 | USE OF SULFATED GLYCOSAMINOGLYCANS FOR ESTABLISHING EFFECTIVE LABOR IN WOMEN - The invention refers to the use of sulfated glycosamino-glycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women. | 10-30-2008 |
| 20080275001 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form. | 11-06-2008 |
| 20080293672 | Lipid conjugates in the treatment of disease - The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof. | 11-27-2008 |
| 20080300219 | NOVEL INTERSTITIAL THERAPY FOR IMMEDIATE SYMPTOM RELIEF AND CHRONIC THERAPY IN INTERSTITIAL CYSTITIS - The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients. | 12-04-2008 |
| 20090036405 | METHOD FOR BLOCKING LIGATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) - A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis. | 02-05-2009 |
| 20090042834 | Stabilized Glycosaminoglycan Preparations and Related Methods - Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.) | 02-12-2009 |
| 20090054374 | METHODS OF TREATING ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention provides methods for treating and preventing acute exacerbations of Chronic Obstructive Pulmonary Disease. The methods particularly comprise administering to a patient have COPD a composition comprising O-desulfated heparin. The administration can be after onset of one or more symptoms indicating an exacerbation of COPD or prior to onset of such symptoms. After onset of an acute exacerbation, administration of the O-desulfated heparin is particularly beneficial for reducing the time of hospitalization of the patient and for reducing lung inflammation. | 02-26-2009 |
| 20090105194 | PROCESS FOR THE PRODUCTION OF A LOW MOLECULAR WEIGHT HEPARIN - The invention provides a process for the production of a very low molecular weight heparin (VLMWH) composition having a VLMWH content, relative to total heparin content, of at least 10% wt, said process comprising chromatographically or chemically or by filtration reducing the relative proportion of heparin having a molecular weight above 8000 Da in a heparin composition extracted from a non-mammalian, vascularised marine animal. | 04-23-2009 |
| 20090105195 | COMPOSITION COMPRISING MICROBICIDAL ACTIVE INGREDIENTS - An antimicrobial composition having a broad-spectrum activity against microorganisms is provided. The antimicrobial composition includes about 0.1 to about 10 percent by weight of a polyurethane polymer of total weight of the antimicrobial composition. The polyurethane polymer is selected from the group consisting of polyolprepolymer and β-Cyclodextrin-polyurethane polymer. The antimicrobial composition further includes about 0.01 to about 5 percent by weight of at least one antiseptic agent of the total weight of the antimicrobial composition. Furthermore, the antimicrobial composition includes at least one microbicidal agent. In addition, the antimicrobial composition includes a pharmaceutically acceptable excipient system. | 04-23-2009 |
| 20090124574 | Carotenoid analogs and derivatives for the prevention of platelet aggregation - The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation. Yet farther embodiments provide for methods of treating a disorder associated with platelet aggregation that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting platelet aggregation in a subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional antiplatelet agents. | 05-14-2009 |
| 20090143330 | Crystalline Polymorphic Forms Of Monosodium N-[-8-(2-Hydroxybenzoyl)Amino]Caprylate - The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino] caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC. | 06-04-2009 |
| 20090143331 | POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY - Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications. | 06-04-2009 |
| 20090149423 | USE FOR A VERY LOW MOLECULAR WEIGHT HEPARINS - The present invention relates to the use of heparin oligosaccharides having a molecular weight≦5050 Da and an anti-factor Xa activity≦80 IU/mg, or their sodium salts, for preparing a medicament for the prevention and treatment of osteoporosis and associated pathologies and for preparing a medicament effective for the prevention and treatment of cerebral ischemia and pathologies related thereto whose treatment necessitates drugs able to cross the blood-brain barrier. | 06-11-2009 |
| 20090149424 | HEPARIN CONJUGATES AND METHODS - Heparin conjugates and methods of making and use thereof are disclosed. An illustrative heparin conjugate includes a composition wherein a bile acid is bonded to heparin through the 3-carbon of the bile acid. A spacer may be interposed between the bile acid and the heparin. Another embodiment includes a targeting moiety bonded to the heparin-bile acid conjugate through a spacer. Another illustrative heparin conjugate includes heparin covalently bonded to a sulfonated moiety, such as a naphthalene trisulfonate residue. A method of treating cancer includes administering a heparin conjugate to an individual in need thereof. | 06-11-2009 |
| 20090181927 | BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS - Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin. | 07-16-2009 |
| 20090281059 | COATING FOR A MEDICAL DEVICE HAVING AN ANTI-THROMBOTIC CONJUGATE - A conjugate between an anti-thrombotic agent and bioabsorbable polymer is provided. Also, a method is provided for applying a coating comprising an anti-thrombotic agent and bioabsorbable polymer conjugate to at least some of an implantable device to prevent or reduce formation of thrombosis on the surface of the device. A first or sub-layer of the coating is prepared by mixing polymeric material and a biologically active agent with a solvent, thereby forming a homogeneous solution. A second or outer layer comprises an anti-thrombotic heparin-bioabsorbable polymer conjugate. This coating may be applied over inner drug-containing layers using, for example, dip coating or spray coating processes. After drying, the anti-thrombotic heparin bioabsorbable polymer conjugate remains in the outer layer of coating, allowing agent from the inner layer to elute there through. Also, the outmost layer prevents thrombosis, and can modulate release kinetics of agent(s) contained within inner layer(s) of the coating. | 11-12-2009 |
| 20100004199 | GLYCINE BETAINE AND ITS USE - The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation. | 01-07-2010 |
| 20100022473 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE - This invention provides for the use of compounds represented by the structure of the general formula (A): | 01-28-2010 |
| 20100069326 | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders - The invention is compositions and methods for treating vascular disorders and/or conditions that involve administering a first agent comprising triflusal (or a triflusal analog or derivative) in combination with at least one other active agent. | 03-18-2010 |
| 20100075922 | HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF - The invention relates to biotinylated heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use. The biotinylated polysaccharides are of the formula (I) | 03-25-2010 |
| 20100081629 | LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF - The invention relates to biotinylated low molecular weight heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use. | 04-01-2010 |
| 20100081630 | Heparin Compositions and Selectin Inhibition - The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selectins. The disclosure also provides Heparins and Heparinoids that modulate the activity of selectins. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject. | 04-01-2010 |
| 20100190744 | COMPOSITIONS AND METHODS OF TREATING VIRAL INFECTIONS - The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, | 07-29-2010 |
| 20100249061 | OLIGOSACCHARIDES, PREPARATION METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for example, during early breast, lung, prostate, colon or pancreatic cancer. The oligosaccharides can be administered subcutaneously, orally or intravenously. Moreover, said oligosaccharides can be used alone or together with other anticancer agents, e.g. cytotoxics such as docetaxel or paclitaxel. | 09-30-2010 |
| 20100273738 | INTEGRATED PATIENT MANAGEMENT AND CONTROL SYSTEM FOR MEDICATION DELIVERY - An integrated patient monitoring and control system is provided which includes a closed-loop control system for monitoring and adjusting the heparin infusion rate for a patient. The system includes a processor which uses a dynamic patient model that is continuously adjusted based on the patient's aPTT measurements to calculate an optimal heparin infusion rate to achieve an operator-input aPTT target range. The processor also includes a forecasting model to calculate the optimum sample time interval for measuring the patient's aPTT to calculate a new infusion rate. An automated sampling system, which includes a storage device for storing a series of assay devices, an advancement mechanism for moving the assay devices to a sample area, and a measurement device for analyzing a sample dispensed on the assay, is provided. The sampling system is used to repeatedly measure the patient's aPTT according to the sample time interval determined by the processor. | 10-28-2010 |
| 20100286087 | PHARMACEUTICAL COMPOSITION, USE OF 2-IMINOPYRROLIDINE DERIVATIVE FOR PRODUCTION OF PHARMACEUTICAL COMPOSITION, AND KIT FOR TREATMENT OR AMELIORATION OF HEART DISEASES - One embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative and at least one other compound (B). Another embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative, which is to be used in combination with at least one other compound (B). According to the present invention, there are provided pharmaceutical compositions capable of treating or ameliorating diseases, such as heart diseases, effectively. | 11-11-2010 |
| 20100292183 | TETRACYCLINE AND USES THEREOF - Provided herein are methods and compositions for the in vitro formation of tetracycline conjugates, for example, tetracycline conjugated to anti-coagulants. The present invention also provides methods for preventing or treating plaque-related diseases or disorders such as atherosclerosis using tetracycline alone, or the tetracycline conjugates of the present invention. | 11-18-2010 |
| 20100298263 | DERIVATIVES OF PARTIALLY DESULPHATED GLYCOSAMINOGLYCANS ENDOWED WITH ANTIANGIOGENIC ACTIVITY AND DEVOID OF ANTICOAGULATING EFFECT - Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds | 11-25-2010 |
| 20100317617 | SILVER NANOPARTICLES AS ANTI-MICROBIAL - A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP. | 12-16-2010 |
| 20110009361 | DESIGN AND SELECTION OF MEDICAMENTS THAT MODULATE THE FUNCTION AND ACTIVITY OF INTERLEUKIN 13 - The present invention relates generally to the field of medicaments in the form of therapeutic molecules including inflammatory modulators and their design and selection. More specifically, the present invention relates to a target site on Interleukin 13 (IL-13) by which a GAG molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function, said target site selected from the list consisting of amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative, and the use of said IL-13 target site to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions comprising the designed medicaments are also contemplated. | 01-13-2011 |
| 20110098247 | Substituted Dihydroquinazolines as Platelet ADP Receptor Inhibitors - Compounds of formula I are provided: | 04-28-2011 |
| 20110112050 | SEPARATION OF POLYSACCHARIDES BY CHARGE DENSITY GRADIENT - Methods and apparatus for the separation of polysaccharides, particular heparin products, and glycosylated molecules are provided. The separation is based on the molecular weight and charge, by application of an electric field across a low-friction matrix, modified with a charged separation agent comprising charged regions ordered in a monotonous sequence distributed throughout the matrix, to generate a charge density gradient formed when an external electric field is applied. Saccharides of different charges migrate differently across the porous matrix and immobilized by charge neutralization in different charge regions of the matrix. | 05-12-2011 |
| 20110124596 | COMPOSITION FOR TREATING INFLAMMATORY DISEASES - The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases. | 05-26-2011 |
| 20110178039 | OLIGOSACCHARIDE MIXTURES DERIVED FROM HEPARIN, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ΔIIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described. | 07-21-2011 |
| 20110201572 | PHARMACEUTICAL COMPOSITION WITH GLYCOSAMINOGLYCANS AND USE THEREOF IN THE TREATMENT OF CHRONIC ULCERS - The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a medicinal product for the treatment of chronic ulcers, and particularly diabetic foot ulcers and pressure ulcers. | 08-18-2011 |
| 20110201573 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. | 08-18-2011 |
| 20110212915 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. | 09-01-2011 |
| 20110281820 | GLYCOSAMINOGLYCANS DERIVED FROM K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITIES AND PROCESS FOR THEIR PREPARATION - Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization. | 11-17-2011 |
| 20110288046 | ANALYSIS OF SULFATED POLYSACCHRIDES - The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described. | 11-24-2011 |
| 20110288047 | PROCESS FOR THE PURIFICATION OF HEPARAN SULFATE AND USE THEREOF IN COSMETOLOGICAL AND DERMATOLOGICAL PREPARATIONS - The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of hepar an sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect. | 11-24-2011 |
| 20110288048 | PROMOTER FOR HARD TISSUE FORMATION - The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent comprising, as an active ingredient, a glycosaminoglycan or a salt thereof that keeps sulfate group and has the characteristics of the following (1) and (2): (1) a basic structure is a disaccharide repeating structure consisting of a hexuronic acid residue and a glucosamine residue, (2) one or less of the position among a 2-position hydroxyl group of a hexuronic acid residue, a 6-position hydroxyl group of a glucosamine residue and a 2-position amino group of the glucosamine residue in the basic structure of the aforementioned (1) does not have the sulfate group. In this connection, it is preferable that the hexuronic acid residue is a glucuronic acid residue or an iduronic acid residue. | 11-24-2011 |
| 20120015904 | BIOMARKERS FOR DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS - The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA). | 01-19-2012 |
| 20120022020 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS - A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan. | 01-26-2012 |
| 20120046241 | DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL IMPAIRMENT - This invention relates to a dose of 10 mg of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment. | 02-23-2012 |
| 20120077773 | USE OF A COMPOSITION FOR THE TREATMENT OF MUCOSITIS - A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin. | 03-29-2012 |
| 20120083465 | METHOD FOR BLOCKING LIGATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) - A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis. | 04-05-2012 |
| 20120083466 | LIPID CONJUGATES IN THE TREATMENT OF ALLERGIC RHINITIS - Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. | 04-05-2012 |
| 20120088736 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]- -5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto - The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof. | 04-12-2012 |
| 20120108541 | ACYLATED 1,6-ANHYDRO DECASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: | 05-03-2012 |
| 20120108542 | SULFATED OCTASACCHARIDE AND ITS USE AS ANTITHROMBOTIC AGENT - The instant invention relates to the octasaccharide of formula (I): | 05-03-2012 |
| 20120108543 | SULFATED HEPTASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the heptasaccharide of formula (I): | 05-03-2012 |
| 20120108544 | ACYLATED DECASACCHARIDES AND THEIR USE AS ANTITHROMBOTIC AGENTS - The instant invention relates to decasaccharides of formula (I): | 05-03-2012 |
| 20120115809 | USE OF AN ACYLATED OCTASACCHARIDE AS AN ANTITHROMBOTIC AGENT - The instant invention relates to the use of the octasaccharide of formula (I), wherein Ac represents an acetyl group: | 05-10-2012 |
| 20120142632 | DIAGNOSTIC AND PROGNOSTIC ASSAY - The present disclosure relates generally to the field of diagnostic and prognostic assays for diseases and conditions of the systemic vasculature. The present disclosure teaches an assay for identifying such a disease or condition of the systemic vasculature as well as classifying and determining the state or stage of the disease or condition or the risk of developing the disease or condition. The assay enabled herein is also useful in the stratification of a subject with respect to a risk of developing various diseases and conditions of systemic vasculature. The assay taught herein is also capable of integration into pathology architecture to provide a diagnostic and reporting system. | 06-07-2012 |
| 20120190645 | Organic compounds - The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery. | 07-26-2012 |
| 20120225843 | Use of Sulfated Glycosaminoglycans for Establishing Effective Labor in Women - A method of treating protracted labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin treated with periodate to eradicate antithrombin III binding affinities, thereby exhibiting an anticoagulant activity of 10 BP units/mg or less and an average molecular weight not higher than 10000 Da to prime or curatively treat the cervix and myometrium and for treatment of slow progress of labor. A method for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in a pregnant woman comprises administering to a pregnant woman an effective amount of a depolymerised low molecular weight heparin as described to prophylactically prime or curatively treat the cervix and myometrium and for establishing effective labor in the pregnant woman. | 09-06-2012 |
| 20120270836 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER'S DISEASE - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder. | 10-25-2012 |
| 20120295871 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS - The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis. | 11-22-2012 |
| 20120316132 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE - The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, (F) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20% by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide. | 12-13-2012 |
| 20120322759 | SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY - The invention relates to an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients receiving chemotherapy for locally advanced or metastatic solid tumors, more specifically in patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer, or for locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3. | 12-20-2012 |
| 20120322760 | METHODS OF TREATMENT WITH A LOW MOLECULAR WEIGHT HEPARIN COMPOSITION - Methods of identifying and selecting subjects for treatment with a low molecular weight heparin (LMWH) composition are provided. Methods of treatment with the LMWH compositions are also provided. | 12-20-2012 |
| 20130005683 | GLYCINE BETAINE AND ITS USE - The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation. | 01-03-2013 |
| 20130012473 | COMBINED USE OF PHOSPHOLIPID AND SULFATE GROUPS-CARRYING POLYSACCHARIDES FOR INHIBITING METASTATIC SPREAD - The invention relates to a medicament comprising a phospholipid component and a polysaccharide component having polysaccharides containing sulfate groups for inhibiting metastatic spread of tumors. The two components may be in same or separate preparation. | 01-10-2013 |
| 20130045946 | SULODEXIDE FOR USE IN THE TREATMENT OF PATHOLOGIES WHEREIN METALLOPROTEINASES ARE INVOLVED - The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies. | 02-21-2013 |
| 20130065851 | ANTI-VIRAL FORMULATIONS - The present disclosure relates generally to the field of anti-viral therapy and prophylaxis. Formulations and agents are provided which inhibit viruses of the Orthomyxoviridae family and ameliorate symptoms and conditions caused by viral infection. The present disclosure teaches the control of influenza virus infection and spread and amelioration of conditions caused thereby. The formulations and agents may be processed as medicaments or as health supplements for more general application such as in the form of consumer goods or consumer foods. | 03-14-2013 |
| 20130065852 | ANALYSIS OF SULFATED POLYSACCHARIDES - The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described. | 03-14-2013 |
| 20130090307 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS - The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination. | 04-11-2013 |
| 20130102564 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING HEPARIN - The present invention relates to a topical pharmaceutical composition comprising heparin and to the use thereof for preventing a functional complication of A-V fistulas and A-V grafts in chronic haemodialysis patients. | 04-25-2013 |
| 20130102565 | SEMULOPARIN FOR THE PREVENTION OF A MORTALITY AND/OR MORBIDITY EVENT IN A PATIENT UNDERGOING MAJOR ORTHOPEDIC SURGERY - The invention relates to the use of semuloparin or a pharmaceutically acceptable salt thereof for the prevention of a mortality and/or morbidity event, more specifically venous thromboembolism and death, in a patient undergoing major orthopedic surgery, such as hip replacement, knee replacement or hip fracture surgery. | 04-25-2013 |
| 20130102566 | SEMULOPARIN FOR USE AS AN ANTITHROMBOTIC TREATMENT IN HIP REPLACEMENT SURGERY WITH IMPROVED SAFETY IN TERMS OF CLINICALLY RELEVANT BLEEDINGS AND MAJOR BLEEDINGS - The invention relates to the use of semuloparin or a pharmaceutically acceptable salt thereof as an antithrombotic treatment in patients undergoing hip replacement surgery, wherein said use involves an improved safety in terms of clinically relevant bleedings and of major bleedings compared to a standard antithrombotic treatment. | 04-25-2013 |
| 20130143840 | HEPARAN SULFATE REPLACEMENT THERAPY - The present invention relates to a method for inhibiting oxidative damage of islet beta cells in vivo in a subject by administering to the subject a therapeutically effective amount of heparan sulfate capable of protecting islet beta cells from reactive oxygen species or in vitro by exposing isolated islet beta cells, prior to transplantation, to a concentration of heparan sulfate that protects them from reactive oxygen species. | 06-06-2013 |
| 20130190270 | Method for Improving Vein Performance in Bypass Surgery - Methods to reduce damage to organelles, cells, tissues, organs and organ systems or components thereof caused by strain due to mechanical stress, including stretch stress and shear stress, are provided. The methods involve treating the organelles, cells, tissues, organs, and organs systems or components thereof (such as veins used for grafts in bypass surgery) with PX-18 and related compounds. Treatment with PX-18 and related compounds reduces damage due to stress and improves the functioning of the cells, tissues, organs or organs systems or components thereof. For example, the methods prevent the buildup of atherosclerotic plaque in transplanted (grafted) veins after coronary bypass surgery. | 07-25-2013 |
| 20130244975 | CHEMICAL CONJUGATES FOR TARGETED DEGRADATION UNDER REDUCING CONDITIONS - The present invention is related to compositions which can undergo targeted degradation under certain physiological reducing conditions. The compositions may, for example, be hydrogels in which maleimide-functionalized low molecular weight heparin is cross-linked with various thiol-functionalized polyethylene glycol multi-arm star polymers. Both the gelation and degradation of the hydrogels can be modified by careful selection of the thiol. For example, hydrogels prepared from aryl thiol-maleimide adducts can undergo a retro Michael addition-type reaction, leading to degradation of the composition and release of the bioactive molecule. | 09-19-2013 |
| 20130303481 | TREATMENT OF MYELOSUPPRESSION - Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids. | 11-14-2013 |
| 20130316973 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CANCER - This invention provides for the use of compounds represented by the structure of the general formula (A): | 11-28-2013 |
| 20140031315 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 01-30-2014 |
| 20140031316 | POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS - The invention relates to sulphated polysaccharides which have the general structure of the constituent polysaccharides of heparin and which have a molecular weight of less than 8000 Daltons, comprising two antithrombin III-binding hexasaccharide sequences corresponding to formula (I) in which: R1 represents an OH group when the hexasaccharide of formula (I) is located at the reducing end of the polysaccharide, or else R1 represents a bond with another saccharide unit of said polysaccharide; R2 represents a hydrogen atom when the hexasaccharide of formula (I) is located at the non-reducing end of the polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit of said hexasaccharide is a double bond, or else R2 represents a bond with another saccharide unit of said polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit is a single bond. Preparation thereof, use thereof as antithrombotic medicaments, and also use thereof in a method for analysing a sample of a heparin derivative. | 01-30-2014 |
| 20140066402 | Pharmaceutical Compositions with Glycosaminoglycans and Use Thereof in the Treatment of Chronic Ulcers - The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a medicinal product for the treatment of chronic ulcers, and particularly diabetic foot ulcers and pressure ulcers. | 03-06-2014 |
| 20140107066 | HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 04-17-2014 |
| 20140162978 | METHOD FOR THE PREVENTION AND TREATMENT OF SEPSIS - This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. The invention provides a novel use of a known medicament, i.e. pentasaccharide-depleted heparin for use in the treatment or prevention of sepsis, SIRS, severe sepsis or septic shock. | 06-12-2014 |
| 20140194380 | METHOD OF MANUFACTURING COMPOSITION COMPRISING LOCAL ANESTHETIC, HEPARINOID, AND BUFFER - An improved method for preparing a composition including a heparinoid, a local anesthetic, and a buffer for treatment of a lower urinary tract disease or condition can comprise either: (A) (i) providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) adding a liquid buffer to the heparinoid in solid form or liquid form; (iv) adding the local anesthetic to the mixture of the liquid buffer and the heparinoid; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 6.8 to about 8.3 is achieved without precipitation of the local anesthetic; or (B) (i)providing a heparinoid in solid form or liquid form; (ii) providing a local anesthetic in solid form or liquid form; (iii) mixing the heparinoid in solid form or liquid form and the local anesthetic in solid form or liquid form; (iv) adding a liquid buffer to the mixture of the heparinoid and the local anesthetic to form a mixture of liquid buffer, the heparinoid, and the local anesthetic; and (v) if necessary, adjusting the pH of the mixture of the liquid buffer, the local anesthetic, and the heparinoid so that a pH is achieved of from about 7.0 to about 7.8 is achieved without precipitation of the local anesthetic. The invention also encompasses a stable premixed liquid composition that avoids precipitation of the local anesthetic. | 07-10-2014 |
| 20140235573 | PREVENTION AND/OR TREATMENT OF CANCER AND/OR CANCER METASTASIS - The present invention relates to the use of heparin derivatives for the prevention and/or treatment of cancer and/or cancer metastasis. The heparin derivatives are substantially 2-O and/or 6-O desulphated heparins which function as inhibitors of galectin-3 activity. | 08-21-2014 |
| 20140303119 | METHODS, APPARATUS, AND COMPOUNDS FOR THE TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION AND OTHER CONDITIONS - The present invention teaches a method and new use for anticoagulant compounds for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) and other conditions. CRVO and BRVO represent debilitating conditions for which there is currently no effective therapy. The present invention teaches a new therapy, including new uses for existing pharmacological agents, comprising enoxaparin sodium, warfarin, clopidrogel, and others, in the treatment of these and other conditions. | 10-09-2014 |
| 20140323434 | LIPID CONJUGATES IN THE TREATMENT OF CHRONIC RFHINOSINUSITIS - This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating, suppressing, inhibiting, or preventing nasal polyps in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. | 10-30-2014 |
| 20140349962 | RAPID TWO-STEP SYNTHESIS OF ANTI-COAGULANTS - The present invention provides methods for the production of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, compounds thus obtained and compositions comprising same. This invention also provides applications of N-deacetylate N-sulfate derivatives of non-sulfated N-acetyl heparosan (HS) polysaccharides, and compositions comprising same, for use in controlling coagulation and treating thrombosis. | 11-27-2014 |
| 20140349963 | AQUEOUS SOLUTION COMPRISING A MACROMOLECULAR CONJUGATE OF HEPARIN FOR THE TREATMENT OF BLOOD VESSELS - The present invention relates to a solution for treating blood vessels where the solution comprises a heparin conjugate. The invention further relates to the use of the conjugate as a medicament and a method of coating tissue using the conjugate. | 11-27-2014 |
| 20140371171 | Aqueous Lock Composition Comprising Ethanol and a Polysaccharide Anticoagulant - The invention relates to an aqueous lock composition comprising a compound selected from the polysaccharide anti-coagulants and ethanol, and a method for locking an intravascular device implanted in a patient comprising the introduction of said composition into the device. | 12-18-2014 |
| 20150011505 | NON ANTI-COAGULATIVE GLYCOSAMINOGLYCANS COMPRISING REPEATING DISACCHARIDE UNIT AND THEIR MEDICAL USE - The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses. | 01-08-2015 |
| 20150045322 | COMBINATION TREATMENT COMPRISING SULPHATED GLYCOSAMINOGLYCANS FOR INDUCING LABOR - The present invention refers to the use of certain sulfated glycosaminoglycans for inducing labor. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are used in a combination therapy together with treatment capable of promoting cervical ripening or capable of promoting myometrial contractions of the uterus. | 02-12-2015 |
| 20150065455 | METHODS OF ASSESSING SUSCEPTIBILITY TO DRUG-INDUCED THROMBOCYTOPENIA - The invention relates to assessing the FcγRIIIa-158 polymorphism in a subject in order to determine susceptibility of the subject to drug induced thrombocytopenia, as well as therapies and therapeutic compositions based on the use of this biomarker. | 03-05-2015 |
| 20150065456 | AGENT FOR TREATMENT AND PREVENTION OF CANCER - The invention provides methods of treating or preventing in a subject a cancer, tumor, or neoplasm, including malignancies or metastases thereof, using a direct Factor Xa inhibitor. The methods particularly involve the treatment of human patients afflicted with a malignant cancer, tumor, or neoplasm with an effective amount of the Factor Xa inhibitor. In an embodiment, the Factor Xa inhibitor is the small molecule edoxaban p-toluenesulfonate monohydrate, also termed “DU-176b”. The invention provides methods of administering a Factor Xa inhibitor to effectively reduce or suppress, or otherwise abrogate, the growth of cancers, tumors, or neoplasms in a subject who has, or is at risk for, cancer and, optionally, who also has, or is at risk for, thrombotic disease or embolism. The methods of the invention can also reduce the incidence of migration or invasion of metastatic or malignant cancers in a human subject by administration of a Factor Xa inhibitor. | 03-05-2015 |
| 20150099718 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS - The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis. | 04-09-2015 |
| 20150105345 | USES OF ANTAGONISTS OF HYALURONAN SIGNALING - Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer. | 04-16-2015 |
| 20150111849 | USE OF HEPARIN AND CARBOHYDRATES TO TREAT CANCER - The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport. | 04-23-2015 |
| 20150126473 | Ultra-Small ApoB-Containing Particles and Methods of Use Thereof - The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided. | 05-07-2015 |
| 20150359816 | STABLE COMPOSITIONS COMPRISING HEPARINOID, ACUTE-ACTING ANESTHETIC, AND BUFFER - Improved methods for preparing compositions including a heparinoid, an acute-acting anesthetic, and a buffer are described. These methods result in compositions in which the heparinoid and the acute-acting anesthetic are at least 90% stable for one year. Compositions prepared by these methods and having such improved stability properties are also described, as well as methods for use of these compositions for treating, ameliorating, or preventing lower urinary tract disorders such as interstitial cystitis. | 12-17-2015 |
| 20160051575 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS - The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis. | 02-25-2016 |
| 20160060366 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 03-03-2016 |
| 20160113959 | Prevention And/Or Treatment Of Cancer And/Or Cancer Metastasis - The present invention relates to the use of heparin derivatives for the prevention and/or treatment of cancer and/or cancer metastasis. The heparin derivatives are substantially 2-O and/or 6-O desulphated heparins which function as inhibitors of galectin-3 activity. | 04-28-2016 |
| 20160120896 | POLYSACCHARIDE COMPOSITIONS AND RELATED METHODS - The disclosure provides LMWH preparations and methods of analyzing LMWH preparations having at least one chain having a glycol split uronic acid residue (UG) in the preparation for structural signatures, and methods of producing such preparations based upon the analysis. | 05-05-2016 |
| 20160122446 | REVERSIBLE HEPARIN MOLECULES AND METHODS OF MAKING AND USING THE SAME - Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine. | 05-05-2016 |
| 20160136278 | EXTERNAL-USE COMPOSITION PRODUCING FOAMED STATE UPON USE - A means for increasing the amount of an effective component retained in a composition for a pump foamer is provided. The present invention provides a composition for external use containing: 1) an N-alkyl-2-pyrrolidone and/or a diester carbonate; and 2) a surfactant; which composition is in a foam state upon use. | 05-19-2016 |
| 20160137754 | NEW PROCESSES FOR THE PRODUCTION OF CHEMICALLY-MODIFIED HEPARINS - The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups. | 05-19-2016 |
